Many target candidates for CAR-T cell therapies against PC are currently under investigation in several clinical trials, among them are mucin 1 (MUC1), Claudin 18.2, prostate stem cell antigen (PSCA), prominin 1 (PROM1), epidermal growth factor receptor (EGFR), and mesothelin (MSLN) [94]. This evidence concerns the gene PROM1 and pachyonychia congenita.